Medeon Biodesign (6499) — Cash Flow Reinvestment Rate

Latest as of March 2022: 5.77x

Medeon Biodesign (6499) has a Cash Flow Reinvestment Rate of 5.77x as of March 2022, reinvesting NT$350.52 Million (capex NT$41.12 Million plus investments NT$309.40 Million) from operating cash flow of NT$60.74 Million. Explore Medeon Biodesign (6499) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

5.77x

(Capex + Investments) / Operating CF

Total Reinvested

NT$350.52 Million

Capex + Investments

Operating Cash Flow

NT$60.74 Million

TWD

Capital Expenditures

NT$41.12 Million

TWD

Medeon Biodesign Cash Flow Reinvestment Rate (2018–2018)

Historical reinvestment intensity for Medeon Biodesign across 1 annual periods. Also explore balance sheet size of Medeon Biodesign for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Medeon Biodesign (2018–2018)

Year-by-year capital reinvestment analysis for Medeon Biodesign. For live market cap and broader valuation context, see market value of Medeon Biodesign.

Year	Reinvestment Rate	Total Reinvested (TWD)	Operating CF	Capex	YoY Change
2018	0.96x	NT$310.54 Million	NT$322.05 Million	NT$51.14 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow